Several other research firms also recently weighed in on RARE. Zacks Investment Research raised Ultragenyx Pharmaceutical from a sell rating to a hold rating in a research note on Tuesday, July 18th. Canaccord Genuity set a $98.00 price objective on Ultragenyx Pharmaceutical and gave the company a buy rating in a research note on Friday, July 28th. BidaskClub downgraded Ultragenyx Pharmaceutical from a buy rating to a hold rating in a research note on Tuesday, August 1st. Jefferies Group LLC reaffirmed a hold rating and issued a $68.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Friday, July 14th. Finally, J P Morgan Chase & Co set a $76.00 price objective on Ultragenyx Pharmaceutical and gave the company a buy rating in a research note on Wednesday, August 23rd. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating and eight have issued a buy rating to the company. The stock presently has a consensus rating of Hold and an average target price of $71.65.
Shares of Ultragenyx Pharmaceutical (RARE) traded down 0.65% during mid-day trading on Tuesday, hitting $52.18. The stock had a trading volume of 86,645 shares. The stock has a 50 day moving average price of $56.51 and a 200-day moving average price of $62.94. Ultragenyx Pharmaceutical has a 52-week low of $49.56 and a 52-week high of $91.35. The company’s market cap is $2.22 billion.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its earnings results on Thursday, July 27th. The biopharmaceutical company reported ($1.72) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.73) by $0.01. During the same period in the previous year, the company earned ($1.46) EPS. On average, equities analysts expect that Ultragenyx Pharmaceutical will post ($7.14) earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Ultragenyx Pharmaceutical’s (RARE) “Buy” Rating Reiterated at Robert W. Baird” was published by Stock Observer and is the property of of Stock Observer. If you are accessing this piece on another website, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.thestockobserver.com/2017/09/22/ultragenyx-pharmaceuticals-rare-buy-rating-reiterated-at-robert-w-baird.html.
In related news, CEO Emil D. Kakkis bought 7,500 shares of the stock in a transaction on Monday, August 28th. The shares were purchased at an average price of $52.52 per share, for a total transaction of $393,900.00. Following the acquisition, the chief executive officer now owns 430,569 shares in the company, valued at $22,613,483.88. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 9.20% of the stock is currently owned by corporate insiders.
Large investors have recently made changes to their positions in the business. Sei Investments Co. acquired a new stake in Ultragenyx Pharmaceutical during the 2nd quarter valued at $125,000. Pacer Advisors Inc. grew its holdings in Ultragenyx Pharmaceutical by 22.6% during the 1st quarter. Pacer Advisors Inc. now owns 3,037 shares of the biopharmaceutical company’s stock valued at $206,000 after buying an additional 560 shares during the last quarter. Strs Ohio grew its holdings in Ultragenyx Pharmaceutical by 10.7% during the 1st quarter. Strs Ohio now owns 3,100 shares of the biopharmaceutical company’s stock valued at $210,000 after buying an additional 300 shares during the last quarter. Ameritas Investment Partners Inc. grew its holdings in Ultragenyx Pharmaceutical by 3.7% during the 1st quarter. Ameritas Investment Partners Inc. now owns 3,226 shares of the biopharmaceutical company’s stock valued at $219,000 after buying an additional 115 shares during the last quarter. Finally, Tocqueville Asset Management L.P. grew its holdings in Ultragenyx Pharmaceutical by 8.0% during the 2nd quarter. Tocqueville Asset Management L.P. now owns 3,375 shares of the biopharmaceutical company’s stock valued at $210,000 after buying an additional 250 shares during the last quarter. Hedge funds and other institutional investors own 96.07% of the company’s stock.
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.
Receive News & Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.